| Ytd | -28.23% | |
| 1y | -44.45% |
| Open | 0.82 | Prev Close | 0.84 | Low | 0.80 | High | 0.86 | Mkt Cap | 12.29M |
| Vol | 264.34K | Avg Vol | 2.36M | EPS | -1.87 | P/E | N/A | Forward P/E | -0.47 |
| Beta | 1.41 | Short Ratio | 0.62 | Inst. Own | 21.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 1.34 | 200-d Avg | 1.83 | 1yr Est | 6.00 |
TRAW News
Traws Pharma, Inc. $139,185,641.25 Common StockPreferred StockDebt SecuritiesWarrantsUnits This pros
The updated data package is expected to be resubmitted to MHRA during the third quarter of 2026. 
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing
HC Wainwright & Co. analyst Brandon Folkes downgrades Traws Pharma (NASDAQ:TRAW) from Buy to
Traws Pharma shares fell after UK regulators deferred a planned influenza challenge study for tivoxa
Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining i
Tower Semiconductor (TSEM) jumped 4.7% in pre-market trading after announcing a multi-year supply ag
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/